학술논문
Management of tumor lysis syndrome in pediatric patients with leukemia: A survey in Japan / わが国の小児白血病における腫瘍崩壊症候群への対応の現状
Document Type
Journal Article
Author
Source
日本小児血液・がん学会雑誌 / The Japanese Journal of Pediatric Hematology / Oncology. 2023, 60(2):143
Subject
Language
Japanese
ISSN
2187-011X
2189-5384
2189-5384
Abstract
Results: We received valid responses from 99 facilities (64%). Urinary alkalinization was performed at initiation of induction therapy in 54% of the institutions, and it was conducted in 67% of the facilities where five or fewer new hematopoietic tumors were reported per year. Uric acid production inhibitors were administered prophylactically in 75% of the facilities. Rasburicase was used in most institutions to treat TLS with an average continuous duration of 5.4 days. Regarding the re-administration of rasburicase, 45% of the respondents reported no adverse effects; however, data from the period between the initial administration and re-administration were not investigated.